Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiationtherapy in patients with borderline resectable pancreatic head cancer

Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiationtherapy in patients with borderline resectable pancreatic head cancer - CMS deployment promises safe neoadjuvant chemoradiationtherapy in patients with borderline resectable pancreatic head cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009683

Enrollment

Registered

2013-01-03

Start date

2013-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

endoscopic biliary stent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Over 20 years old, Borderline resectable pancreatic head cancer based on NCCN guideline 2012.

Exclusion criteria

Exclusion criteria: Under the age of 19, non-Borderline resectable pancreatic head cancer based on NCCN guideline 2012.

Design outcomes

Primary

Measure	Time frame
Days to reintervention (DR), reintervention rate, the rate of R0 and complications were studied. Safe margin-negative resection (R0) surgery is defined as Ro surgery without reintervention during the NACRT period and no post operative complication.	—

Countries

Japan

Contacts

Public Contactkensuke kubota

Yokohama City University Endoscopy

045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026